Quantgene and CureMatch Announce Strategic Partnership To Help Cancer Patients Find the Best Precision Treatment

Quantgene, Inc. and CureMatch, Inc. have announced a strategic partnership to combine genomic, cloud and AI technologies and improve precision treatments and long-term outcomes for patients diagnosed with cancer.

Quantgene Liquid uses blood samples of cancer patients to help provide a systemic understanding of the mutational profiles of a tumor, also known as a “Liquid Biopsy”. Liquid Biopsies allow physicians to understand the mutational status of tumors without being limited to just a biopsy from a specific part of the tumor. By profiling cell-free DNA fragments in the blood, Quantgene Liquid allows better insights into both primary and metastatic tumors. Quantgene Liquid’s technology is a highly accurate and precise cancer mutation detection system.

Recommended AI News: Side Becomes A Unicorn Company Following $150 Million Series D Financing

The CureMatch Decision Support System provides actionable intelligence to oncologists.  CureMatch supports the doctor with therapy options matched specifically to a patient’s unique molecular tumor profile. The clinical decision support system leverages proprietary algorithms, as well as curated clinical and scientific knowledge, and provides a matching score to help doctors identify combination and monotherapies for optimal cancer treatment.

By combining both technologies, patients and oncologists can now get access to a turnkey solution that requires just a simple blood draw to match them to appropriate cancer therapies. Cancer patients can get results in as little as 3 weeks from a blood draw, to a Quantgene test result to a CureMatch report that informs their precision treatment.

Recommended AI News: Bruin Sports Capital Reaches Agreement with Quadrant Private Equity To Become Co-Owner of Global Sports Technology Company: TGI Sport

In addition to ensuring a successful combination of these two products, the companies will collaborate more closely on advancing Genomics and AI-guided oncology solutions.

Jo Bhakdi, founder and CEO of Quantgene said of the partnership: “Deep Genomics and AI can be a game-changer for cancer patients. New combination treatments can significantly improve outcomes. But sadly until now, the majority of patients didn’t have access to the genomics and AI technologies required to get there. Together with CureMatch, we can make precision treatment insights available to everyone through a simple blood draw.”

Navid Alipour, CEO of CureMatch added, “We are honored and excited to integrate with Quantene’s innovations. Their ability to unlock the human genome and further inform our decision support system for oncology, complements the CureMatch precision medicine solution and supports our mission of helping to extend and save lives.” 

Recommended AI News: Neudata Launches Alt Data Legal and Compliance Intelligence Tool Neudata Sentry